explore -WSS

explore

author：focus 2025-09-06 04:41:02 - browse：3763

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Colonoscopy at 40? Study finds a possible benefit

WSS

Cancer cells are shown to suck energy source from immune cells

A revolution in caring for preterm infants

Gene therapy has helped boys walk. Can scientists keep it that way?

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

STAT Readout: Today's biotech news includes Sana and Amylyx

What the Wegovy shortage looks like for doctors — and for patients

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Jerome Adams on the need for new antivirals for Covid

Death of patient in Alzheimer’s trial raises question of possible risks

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: Merger Mondays, Ozempic panic

ChatGPT in medicine: STAT answers readers' burning questions

Ask STAT: What do you want to know about ChatGPT in medicine?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT's guide to the next generation of CAR

Medicare details structure of new drug price negotiation program

Why are elite athletes different? Take a look at their microbes

hotspot

Life sciences deals on track to hit lowest point since 2017

Better Therapeutics data on benefit with GLP

The story of mRNA: From a loose idea to a tool that may help curb Covid

Takeaways from AdvaMed, the largest medical devices conference

Better Therapeutics data on benefit with GLP

A fraught question for the kids of Alzheimer’s: Is it coming for us?

leisure time

explore

hotspot

leisure time